Cabaletta Bio, Inc

(NASDAQ:CABA)

Latest On Cabaletta Bio, Inc (CABA):

Date/Time Type Description Signal Details
2023-05-18 16:00 ESTNewsCabaletta Bio up 1%, prices $87M offeringN/A
2023-05-18 02:29 ESTNewsCabaletta Bio commences underwritten public offering of sharesN/A
2023-05-16 23:33 ESTNewsCabaletta Bio jumps 16% as FDA clears trial for myositis candidateN/A
2023-05-11 15:27 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.02N/A
2023-05-01 18:20 ESTNewsCabaletta's potential lupus drug CABA-201 gets FDA fast track tagN/A
2023-04-28 03:16 ESTNewsCabaletta Bio: Speculative Biotech With OpportunityN/A
2023-03-31 16:02 ESTNewsCabaletta CAR T cell therapy for lupus gets FDA nod to enter trialN/A
2023-03-31 16:02 ESTNews4 stocks to watch on Friday: Amazon, Kraft Heinz, and moreN/A
2023-03-16 13:19 ESTNewsCabaletta Bio GAAP EPS of -$0.52 misses by $0.08N/A
2023-01-27 17:59 ESTNewsCabaletta rises as Morgan Stanley upgrades citing new CAR-T assetN/A
2023-01-25 12:46 ESTNewsCabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)N/A
2022-12-08 20:30 ESTNewsCabaletta Bio dips on announcing $35M offeringN/A
2022-11-10 11:40 ESTNewsCabaletta Bio GAAP EPS of -$0.39 beats by $0.09N/A
2022-08-30 16:03 ESTNewsCabaletta downgraded at Morgan Stanley on upcoming data for lead assetN/A
2022-08-11 21:46 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.05N/A
2022-05-18 20:14 ESTNewsCabaletta Bio updates Phase 1 interim data for lead assetN/A
2022-05-12 11:04 ESTNewsCabaletta Bio GAAP EPS of -$0.45N/A
2022-03-18 09:46 ESTNewsCabaletta Bio GAAP EPS of -$0.49 beats by $0.11N/A
2021-12-14 08:41 ESTNewsCabaletta Bio tanks 34% on cell therapy data in early-stage study for pemphigus vulgarisN/A
2021-11-01 14:01 ESTNewsCabaletta Bio EPS beats by $0.05N/A
2021-11-01 14:01 ESTNewsCabaletta rises as skin diseases drug shown to be safe in early data of phase 1 trialN/A
2021-08-19 00:00 ESTNewsCabaletta Bio reports results from DesCAARTes trial in patients with pemphigus vulgarisN/A
2021-08-05 20:25 ESTNewsCabaletta Bio EPS beats by $0.03N/A
2021-03-18 15:25 ESTAnalyst RatingThe Analyst Target Price has increased from $20.33 to $22.25.Buy
2021-03-18 07:46 ESTFinancialsCompany financials have been released.Neutral
2021-03-17 17:01 ESTNewsCabaletta Bio EPS misses by $0.04N/A
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$2.18 is estimated for the 2022 year.Sell
2021-01-20 12:58 ESTNewsCabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young BiotechN/A
2021-01-11 10:22 ESTAnalyst RatingThe Analyst Target Price has increased from $20 to $20.33.Buy
2021-01-09 03:37 ESTNewsChardan Capital initiates Cabaletta Bio with Buy ratingN/A
2020-12-10 06:47 ESTNewsDosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorderN/A
2020-12-04 06:26 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 15:51 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.67 to $20.Neutral
2020-11-17 07:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 23:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 07:15 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 09:52 ESTNewsCabaletta Bio EPS beats by $0.08N/A
2020-11-11 09:52 ESTNewsCabaletta Bio +5% on Q3 results, pipeline updateN/A
2020-11-11 06:54 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.Sell
2020-10-15 08:02 ESTNewsCabaletta Bio (CABA) Investor Presentation - SlideshowN/A
2020-10-14 11:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $22.5 to $21.67.Neutral
2020-10-08 21:07 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:25 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:38 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 09:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-10 03:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 23:40 ESTFinancialsCompany financials have been released.Neutral

About Cabaletta Bio, Inc (CABA):

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.

See Advanced Chart

General

  • Name Cabaletta Bio, Inc
  • Symbol CABA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 31
  • Fiscal Year EndDecember
  • IPO Date2019-10-25
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.cabalettabio.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.23
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.13
  • Next Year EPS Estimate -$2.45
  • Next Quarter EPS Estimate -$0.42
  • Return on Assets -17%
  • Return on Equity -27%
  • Earnings Per Share -$0.94
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 276.24 million
  • Analyst Target Price $22.25
View More

Share Statistics

  • Shares Outstanding 24.06 million
  • Shares Float 7.91 million
  • % Held by Insiders 523%
  • % Held by Institutions 67.4%
  • Shares Short 1.63 million
  • Shares Short Prior Month 1.61 million
  • Short Ratio 15.52
  • Short % of Float 8%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • 52 Week High $16.38
  • 52 Week Low $6.07
  • 50 Day Moving Average 11.96
  • 200 Day Moving Average 12.4
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cabaletta Bio, Inc (CABA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cabaletta Bio, Inc (CABA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$N/A-$0.40-$0.36-11.11%
2020-09-302020-11-10$N/A-$0.36-$0.4418.18%
2020-06-302020-08-06$N/A-$0.35-$0.3910.26%
2020-03-312020-05-12$N/A-$0.33-$0.23-43.48%
2019-12-312020-03-30$N/A-$0.33-$0.4729.79%
2019-09-302019-12-05$N/A-$1.21-$2.2646.46%

Cabaletta Bio, Inc (CABA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Cabaletta Bio, Inc (CABA) Chart:

Cabaletta Bio, Inc (CABA) News:

Below you will find a list of latest news for Cabaletta Bio, Inc (CABA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cabaletta Bio, Inc (CABA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-02-200.51.9CALL0 13736.15TRUE00
2026-02-2011.65CALL0 120438.53TRUE00
2026-02-201.51CALL0 3120TRUE00
2026-02-2020.55CALL0 39210TRUE00
2026-02-202.50.25CALL160 10289115.75TRUE0.090.56
2026-02-2030.12CALL528 1458148.88FALSE0.020.2
2026-02-203.50.02CALL2 290199.74FALSE0.020
2026-02-2040.01CALL0 402287.12FALSE00
2026-02-204.50.04CALL0 1847.83FALSE00
2026-02-2050.04CALL0 3392322.08FALSE00
2026-02-205.50CALL0 0920.63FALSE00
2026-02-207.50.03CALL0 311378.42FALSE00
2026-02-200.50PUT0 0738.1FALSE00
2026-02-2010.05PUT0 2543.12FALSE00
2026-02-201.50.05PUT0 232407.27FALSE00
2026-02-2020.1PUT0 221208.47FALSE00
2026-02-202.50.2PUT0 1197117.19FALSE00
2026-02-2030.4PUT2 66138.64TRUE-0.16-0.29
2026-02-203.51PUT0 20TRUE00
2026-02-2040PUT0 00TRUE00
2026-02-204.50PUT0 0242.06TRUE00
2026-02-2052.05PUT0 00TRUE00
2026-02-205.50PUT0 00TRUE00
2026-02-207.55.25PUT0 0492.65TRUE00
2026-03-200.50CALL0 0375.35TRUE00
2026-03-2010CALL0 0275.7TRUE00
2026-03-201.51CALL1 1261.94TRUE10
2026-03-2020.58CALL0 32104.07TRUE00
2026-03-202.50.5CALL21 44136.34TRUE0.251
2026-03-2030.3CALL93 148131.54FALSE-0.1-0.25
2026-03-203.50.15CALL5 380120.26FALSE0.150
2026-03-2040CALL0 0146.74FALSE00
2026-03-204.50CALL0 0434.37FALSE00
2026-03-2050.2CALL0 18454.37FALSE00
2026-03-205.50CALL0 0471.76FALSE00
2026-03-200.50PUT0 0379.26FALSE00
2026-03-2010PUT0 00FALSE00
2026-03-201.50PUT0 0395.77FALSE00
2026-03-2020PUT0 0479.47FALSE00
2026-03-202.50.4PUT0 41115.66FALSE00
2026-03-2030.55PUT0 8119.54TRUE00
2026-03-203.51.05PUT0 13124.12TRUE00
2026-03-2040PUT0 0131.9TRUE00
2026-03-204.50PUT0 0128.61TRUE00
2026-03-2050PUT0 0145.43TRUE00
2026-03-205.50PUT0 0186.86TRUE00
2026-05-150.50CALL0 0235.72TRUE00
2026-05-1511.2CALL0 920TRUE00
2026-05-151.51.2CALL0 21383.54TRUE00
2026-05-1521CALL0 142991.95TRUE00
2026-05-152.50.6CALL119 17171105.56TRUE-0.03-0.05
2026-05-1530.45CALL0 520149.57FALSE00
2026-05-153.50.4CALL0 413145.07FALSE00
2026-05-1540.4CALL0 147260.52FALSE00
2026-05-154.50.3CALL0 22188.76FALSE00
2026-05-1550.24CALL0 3665152.23FALSE00
2026-05-155.50CALL0 0299.31FALSE00
2026-05-157.50.07CALL0 705158.34FALSE00
2026-05-150.50PUT0 0299.34FALSE00
2026-05-1510PUT0 00FALSE00
2026-05-151.50PUT0 0450.98FALSE00
2026-05-1520.4PUT0 3306.87FALSE00
2026-05-152.50.65PUT0 449140.75FALSE00
2026-05-1530PUT0 0115.97TRUE00
2026-05-153.51.38PUT0 3121.75TRUE00
2026-05-1540PUT0 0131TRUE00
2026-05-154.50PUT0 0125.37TRUE00
2026-05-1552.5PUT0 24159.7TRUE00
2026-05-155.50PUT0 0149.25TRUE00
2026-05-157.54.15PUT0 33183.31TRUE00
2026-08-210.52.6CALL0 2161.36TRUE00
2026-08-2110CALL0 00TRUE00
2026-08-211.51.6CALL0 10113.31TRUE00
2026-08-2121.2CALL1 27133.64TRUE1.20
2026-08-212.50.85CALL4025 1691108.71TRUE00
2026-08-2131.1CALL0 248103.55FALSE00
2026-08-213.50.7CALL0 26127.23FALSE00
2026-08-2140.75CALL1 4147.1FALSE0.750
2026-08-214.50CALL0 0144.55FALSE00
2026-08-2150.5CALL0 3147.04FALSE00
2026-08-215.50.5CALL0 1154.94FALSE00
2026-08-210.50PUT0 00FALSE00
2026-08-2110PUT0 00FALSE00
2026-08-211.50PUT0 0318.71FALSE00
2026-08-2120PUT0 0217.04FALSE00
2026-08-212.50.9PUT0 1118.72FALSE00
2026-08-2131.05PUT0 1131TRUE00
2026-08-213.50PUT0 0134.63TRUE00
2026-08-2140PUT0 0141.82TRUE00
2026-08-214.50PUT0 0140.04TRUE00
2026-08-2150PUT0 0156.59TRUE00
2026-08-215.50PUT0 0165.21TRUE00
2026-09-180.52.2CALL0 160TRUE00
2026-09-1812CALL0 7146.66TRUE00
2026-09-181.51.26CALL0 60138.69TRUE00
2026-09-1821.3CALL0 1019124.47TRUE00
2026-09-182.51.3CALL3 6759167.46TRUE0.30.3
2026-09-1830.9CALL0 290149.34FALSE00
2026-09-183.50.9CALL0 350150.73FALSE00
2026-09-1840.85CALL0 2149.82FALSE00
2026-09-184.50.65CALL0 10147.26FALSE00
2026-09-1850.75CALL1 285155.79FALSE0.750
2026-09-185.50CALL0 0150.76FALSE00
2026-09-187.50.4CALL0 545140.93FALSE00
2026-09-180.50PUT0 00FALSE00
2026-09-1810PUT0 00FALSE00
2026-09-181.50PUT0 0178.7FALSE00
2026-09-1820PUT0 0131.07FALSE00
2026-09-182.50.9PUT0 38136.53FALSE00
2026-09-1831.25PUT0 38150.01TRUE00
2026-09-183.51.65PUT0 7145.78TRUE00
2026-09-1840PUT0 0152.27TRUE00
2026-09-184.50PUT0 0150.47TRUE00
2026-09-1852.7PUT0 8159.78TRUE00
2026-09-185.50PUT0 0155.44TRUE00
2026-09-187.50PUT0 0126.87TRUE00
2027-01-150.52.69CALL0 10TRUE00
2027-01-1511.8CALL0 2160.97TRUE00
2027-01-151.52.4CALL0 1119.17TRUE00
2027-01-1521.7CALL1 10173.09TRUE1.70
2027-01-152.51.22CALL0 257130.72TRUE00
2027-01-1531.25CALL0 185167.67FALSE00
2027-01-153.51.3CALL0 6165.94FALSE00
2027-01-1541CALL0 21168.98FALSE00
2027-01-154.51CALL0 20165.17FALSE00
2027-01-1550.75CALL0 50188.88FALSE00
2027-01-155.51CALL1 1156.17FALSE10
2027-01-150.50PUT0 00FALSE00
2027-01-1510PUT0 00FALSE00
2027-01-151.50.65PUT0 12184.66FALSE00
2027-01-1520.76PUT0 52135.36FALSE00
2027-01-152.51PUT0 14136.56FALSE00
2027-01-1530PUT0 0152.53TRUE00
2027-01-153.50PUT0 0158.98TRUE00
2027-01-1541.96PUT0 50181.23TRUE00
2027-01-154.50PUT0 0177.99TRUE00
2027-01-1550PUT0 0185.57TRUE00
2027-01-155.53.2PUT0 50181.02TRUE00
2028-01-210.53.1CALL0 7139.36TRUE00
2028-01-2112.5CALL0 2169.62TRUE00
2028-01-211.51.86CALL0 44201.74TRUE00
2028-01-2121.72CALL0 103172.9TRUE00
2028-01-212.51.75CALL0 207144.23TRUE00
2028-01-2131.95CALL0 55168.24FALSE00
2028-01-213.50CALL0 0174.61FALSE00
2028-01-2141.85CALL3 1167.73FALSE1.850
2028-01-214.51.95CALL0 10161.44FALSE00
2028-01-2151.64CALL0 27176.37FALSE00
2028-01-215.51.5CALL0 77169.18FALSE00
2028-01-210.50PUT0 00FALSE00
2028-01-2110PUT0 0170.71FALSE00
2028-01-211.50PUT0 0164.37FALSE00
2028-01-2120PUT0 0172.96FALSE00
2028-01-212.50PUT0 0170.53FALSE00
2028-01-2130PUT0 0173.98TRUE00
2028-01-213.50PUT0 0164.02TRUE00
2028-01-2140PUT0 0171.5TRUE00
2028-01-214.50PUT0 0156.77TRUE00
2028-01-2153.3PUT0 43172.78TRUE00
2028-01-215.50PUT0 0178.03TRUE00

Latest CABA Trades:

Date Shares Price
Jun 13, 2022 7:37 PM EST1$1.08
Jun 13, 2022 7:37 PM EST6$1.08
Jun 13, 2022 7:51 PM EST7$1.06
Jun 13, 2022 7:57 PM EST7$1.06
Jun 13, 2022 7:58 PM EST7$1.055

Cabaletta Bio, Inc (CABA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025941/0000899243-19-025941-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025942/0000899243-19-025942-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025943/0000899243-19-025943-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025946/0000899243-19-025946-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025947/0000899243-19-025947-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026016/0000899243-19-026016-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026017/0000899243-19-026017-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026018/0000899243-19-026018-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026020/0000899243-19-026020-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026345/0000899243-19-026345-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026346/0000899243-19-026346-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004509/0000899243-20-004509-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004511/0000899243-20-004511-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006864/0000899243-20-006864-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006865/0000899243-20-006865-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006867/0000899243-20-006867-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320025326/0000899243-20-025326-index.htm
2020-07-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000090266420002724/0000902664-20-002724-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963819000988/0000929638-19-000988-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963820000331/0000929638-20-000331-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919056233/0001104659-19-056233-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919057348/0001104659-19-057348-index.htm
2019-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-11-12SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1759138/000110465919061822/0001104659-19-061822-index.htm
2019-10-24S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519273939/0001193125-19-273939-index.htm
2019-10-25424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519274807/0001193125-19-274807-index.htm
2019-10-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519277804/0001193125-19-277804-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312519278927/0001193125-19-278927-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519287367/0001193125-19-287367-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520005110/0001193125-20-005110-index.htm
2020-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520017724/0001193125-20-017724-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520038349/0001193125-20-038349-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520042689/0001193125-20-042689-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520090013/0001193125-20-090013-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520091086/0001193125-20-091086-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520115863/0001193125-20-115863-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520134391/0001193125-20-134391-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520139782/0001193125-20-139782-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/0001193125-20-153792-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520211336/0001193125-20-211336-index.htm
2019-10-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001374/0001193805-19-001374-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380520000185/0001193805-20-000185-index.htm
2019-12-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459019045375/0001564590-19-045375-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1759138/000156459020013929/0001564590-20-013929-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020024508/0001564590-20-024508-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020037278/0001564590-20-037278-index.htm
2019-10-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1759138/999999999519002384/9999999995-19-002384-index.htm

Cabaletta Bio, Inc (CABA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cabaletta Bio, Inc (CABA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 523%
Institutional Ownership: 6740%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-10-295AM Ventures V, L.P.10% Share HolderBuy454,545.0011.004,999,995.00454,545.00https://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-10-29James E Flynn10% Share HolderBuy700,000.0011.007,700,000.00700,000.00https://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm